US 12,234,246 B2
Solid state forms of baloxavir marboxil
Anantha Rajmohan Muthusamy, Sivakasi (IN); Amit Singh, Greater Noida (IN); Amol Gulab Khatik, Nagpur (IN); Sundara Lakshmi Kanniah, Greater Noida (IN); Yogesh Dhananjay Wagh, Greater Noida (IN); Parven Kumar Luthra, Thane (IN); Brijnath P. Chaurasia, G.B. Nagar District (IN); and Ram Karan Prajapati, Greater Noida (IN)
Assigned to ASSIA CHEMICAL INDUSTRIES LTD., Tel Aviv (IL)
Appl. No. 17/435,824
Filed by ASSIA CHEMICAL INDUSTRIES LTD., Petach Tikva (IL)
PCT Filed Mar. 5, 2020, PCT No. PCT/US2020/021062
§ 371(c)(1), (2) Date Sep. 2, 2021,
PCT Pub. No. WO2020/181025, PCT Pub. Date Sep. 10, 2020.
Claims priority of application No. 201911008540 (IN), filed on Mar. 5, 2019; application No. 201911011504 (IN), filed on Mar. 25, 2019; application No. 201911036007 (IN), filed on Sep. 6, 2019; application No. 202011005438 (IN), filed on Feb. 7, 2020; and application No. 202011005457 (IN), filed on Feb. 7, 2020.
Prior Publication US 2022/0153753 A1, May 19, 2022
Int. Cl. C07D 498/14 (2006.01); A61P 31/12 (2006.01)
CPC C07D 498/14 (2013.01) [A61P 31/12 (2018.01)] 18 Claims
 
1. A crystalline form of baloxavir marboxil designated as Form BM3, characterized by data selected from one or more of the following:
an XRPD pattern having peaks at: 5.2, 10.1, 15.2, 18.3 and 19.6 degrees 2-theta±0.2 degrees 2-theta;
an XRPD pattern substantially as depicted in FIG. 4; or
combinations of these data.